Introduction
Basic science can be undertaken for a number of reasons, but increasingly there is a desire among translational neuroscientists to bring their discoveries to the clinic and ultimately to advance the health of people with diseases of the brain or nervous system. Laboratory scientists who make a discovery that leads to a breakthrough treatment or prevention of an otherwise untreatable condition can be immeasurably rewarded for their contributions. However, many neuroscientists have also experienced enormous disappointment when their promising intervention fails in clinical development. Such failures can negate years of effort and waste enormous expenditure of resources. Unfortunately, this type of failure is all too common among therapies for CNS diseases such as ALS, Alzheimer's disease, Parkinson's disease, and others (Benatar, 2007; Franco and CedazoMinguez, 2014; Katsuno et al., 2012) . While all such failures cannot be prevented, some may be traced back to a lack of partnering between neuroscientists working on discoveries in the laboratory and clinical scientists who assess treatments in human disease. The worlds that these two types of scientists inhabit are both very complex. Both require years of specialized training. While the clinical scientist will rarely have the responsibility of worrying about how his or her work is translated back into the laboratory (although sometimes this happens), the laboratory scientist interested in clinical intervention should most certainly understand the concepts of the clinical development path.
The purpose of this article is to provide a ''how to'' for translational scientists and to outline some of the major issues that often lead to an inability to bring a big discovery across the translational divide. The authors include scientists working on both sides of the translation gap in the field of epilepsy. As a group, we have seen both successes and failures in the clinic, and in some cases the reasons for these have become evident, even if only in hindsight. Where possible, examples will be provided. Although these examples are mostly in the epilepsy field, we will be discussing issues that are generalizable to other areas of CNS therapy. We will not cover issues of lack of preclinical rigor. Whereas this is an extremely important reason for failure of translation, it is covered elsewhere in this issue.
Types of Therapeutic Intervention
Because the issues will vary based on the intent of the therapy, we will begin with a brief discussion of the three main areas of therapeutic intervention. These include symptomatic control, disease modification/cure, and disease prevention.
Control of Symptoms
Treatment for control of symptoms provides relief while the treatment is administered but does not alter the underlying disease or its course. Examples include seizure suppression in patients with epilepsy, symptomatic headache therapies, and improvement of memory in patients with Alzheimer's disease. Often many pathways are available for intervention, and there are animal models that translate reasonably well to the clinic, making highthroughput screening a possibility in some cases. Also, therapies may already exist for these purposes, and therefore the regulatory pathways are well understood. Translation of therapies for symptomatic control are probably the most likely to succeed, although even here there are pitfalls such as dose determination, safety assessment, and determining whether the treatment is better than existing treatments. All of these issues are addressed below. Disease Modification/Cure Disease modification comprises an alteration of the underlying pathophysiology before or after the disease has clinically manifested, leading to an improvement or change in progression of the disease or its comorbidities. Successful translation of a disease-modifying intervention requires a more fundamental understanding of the underlying pathophysiology of the disease in question. This complete understanding will most often come as a result of cross-communication and collaboration between clinician and basic researcher. The translation of a diseasemodifying treatment is often predicated on one of two scenarios. In scenario 1, clinical investigation of the human disease leads to identification of a fundamental mechanism of disease, and preclinical science identifies a way to modulate that mechanism. In this case, translation may fail because the mechanism identified was not essential in the disease pathophysiology, or the effect size of the intervention was not great enough, among other reasons. As an example, failures in clinical trials for both Alzheimer's disease and Parkinson's disease have potentially been due to a modest effect in large patient cohorts at diverse stages of the disease severity (Cedernaes et al., 2014; Pinna, 2014) . It is possible that future successes in clinical trials for both of these disorders, e.g., amyloid beta-targeting antibodies for AD and adenosine A2 receptor antagonists for PD, may come through a better understanding of the role of that target in the disease pathology or better identification of relevant patient populations. In scenario 2, which is much more risky, an animal model of the disease has been created (e.g., the ALS mouse, the Alzheimer's prone mouse, etc.), and an intervention has been demonstrated to reduce or eliminate disease in the animal model. This scenario can be very enticing to a translational scientist, particularly when there is some apparent overlap between the pathology of the human disease and the pathology seen in the animal model. For example, a toxic gain-of-function mutation in chromosome 21, which codes for superoxide dismutase, produces ALS in both humans (familial ALS) and mice. Yet, therapies that slow progression of disease in the animal model have failed to impact human disease (Benatar, 2007) . Unfortunately, disease modification/cure is intimately linked with mechanisms of development and progression of disease, and these have yet to be clearly determined to be comparable between animal models and human. Appropriate timing of intervention will also be a factor, and this is discussed below. In general, diseases can be attributed to a predisposing insult or genetic susceptibility, which may or may not be exacerbated by multiple hits prior to disease onset. It is hypothesized that biomarkers of disease susceptibility and biomarkers of various contributors to the chronic disease state exist or can be identified for most clinical conditions.
Disease Prevention
Disease prevention may be very straightforward in some cases, where the approach is to prevent the insult that produces disease from occurring (for example, antiplatelet agents to prevent recurrent stroke, motorcycle helmets to prevent traumatic brain injury). In almost every other scenario, this may be the most risky of all translational objectives. Outside of insult prevention, it is difficult to even think of a scenario in which such an approach has been successful in the CNS, presumably because most CNS diseases have complex pathophysiology and because most of the diseases (ALS, multiple sclerosis, and epilepsy, to name a few) are insidious in their origin. As can be seen in Figure 1 , some mechanisms that promote disease initiation may be present even before the purported onset of the disease but may only be activated by a second or third hit. It may be very difficult to pinpoint the moment that disease becomes inevitable. Also, in essentially every case, a disease prevention therapy will be a first-in-class therapy, and issues related to this will be discussed below.
Is a Proposed Therapy Better than Existing Therapies?
In areas where therapies already exist (mostly therapies to control symptoms), there is still a potential for a breakthrough therapy if the novel therapy is demonstrated to be substantially better than existing therapies. The expectation that a therapy may represent a substantial advance may come from the fact that the drug works through a different mechanism than its predecessors or from evidence of improved benefit over currently available standards of care in an etiologically relevant animal model. In some neurological diseases, e.g., pain and epilepsy, numerous preclinical models exist with translational validity (Lö scher, 2011), whereas in other disease states, e.g., ALS and stroke, the search continues for clinically validated animal models (Perrin, 2014) .
Both scenarios carry challenges for the translation of revolutionary therapies. Epilepsy therapies can act as an example. On the one hand, ample models of acute and chronic seizures have benefited the patient with epilepsy by advancing treatments to the clinic for the symptomatic management of seizures. On the other hand, many years of testing in these models have ultimately demonstrated that they cannot be used to identify breakthrough therapies. The animal models routinely used, e.g., maximal electroshock (MES), do not substantially differentiate compounds in relation to relative efficacy in the clinic or to the potential for reduced side-effect profiles. In the case of epilepsy, carisbamate is an example of an agent that demonstrated a promising preclinical profile in these models but failed to live up to expectations in the clinic. Carisbamate demonstrated efficacy in phase II trials (Novak et al., 2007) but failed to meet the study endpoints in later trials (Halford et al., 2011) . This resulted in the FDA never approving carisbamate for partial-onset seizures, despite the preclinical efficacy in relevant animal models (Bialer et al., 2009) . There is now a concerted effort to develop and implement new preclinical models of epilepsy (Barton et al., 2001; Bouilleret et al., 1999; D'Ambrosio et al., 2013; Stewart et al., 2010) in an attempt to overcome the perceived similarity in efficacy of many antiseizure drugs. These new models may be useful in the identification, differentiation, and development of compounds with novel mechanisms of action, attempting not only to confer an improved antiseizure effect (particularly in the patients who have been resistant to all available therapies), but ideally to modify the course of the underlying disease (disease modification and perhaps even antiepileptogenesis; Kelley et al., 2009; Lowenstein, 2011) .
Levetiracetam is an example of a recent symptomatic treatment for the management of pharmacoresistant epilepsy (Abou-Khalil, 2008; Klitgaard and Verdru, 2007) that is efficacious, has a novel mechanism of action, and has a good tolerability profile. The drug is extremely successful and appears different than other therapies, yet it did not demonstrate efficacy in several of the historical animal models, like MES. It did show efficacy in other, less-frequently used models (Klitgaard et al., 1998) , thereby strongly differentiating it from existing therapies. In this case, the differentiation appears to have been of greater relevance in the clinic than differences demonstrated in the older, standard models. With this in mind, when a new model is implemented, its ability to differentiate a new compound for different treatment aspects (tolerability, efficacy, relevance to a specific population) must be proven in the clinic repeatedly. Unfortunately, this is often not possible where no superior current therapies exist for a condition. For example, several new animal models have been proposed that mimic the devastating epilepsy condition of infantile spasms (Galanopoulou, 2013; Jequier Gygax et al., 2014) . Since few currently available therapies are effective in this syndrome, it is presently difficult to predict how relevant efficacy in one or more of these models will translate to the human condition. The ability of a translational scientist to convince others that the model is relevant will be critical in persuading a sponsor to support translational work, and ultimately the clinician to enroll a specific population in a trial, based on efficacy in that model.
Preclinical Evaluation in the Absence of Existing Therapies
On the other hand, disease states wherein a clinically validated animal model does not yet exist suffer a constrained selection of impactful therapies, few of which have even the potential to improve quality of life in the short term. For example, ALS patients face nearly the same prognosis today as they did 75 years ago when Lou Gehrig first brought the disease to public attention. Over the last decade, a number of promising preclinical compounds have advanced to clinical trials, but only riluzole has demonstrated even a modest effect on clinical outcomes (Gordon, 2005; Perrin, 2014) .
Unfortunately, more failures than successes predominate in the clinical trial arena for neurological diseases. As noted above, a number of factors could be attributed to these failures: poorly designed preclinical or clinical studies (Doody et al., 2014; Gordon, 2005; Perrin, 2014) , animal models that do not fully recapitulate the human condition (Blesa et al., 2012) , or even a continued misunderstanding of a particular factor in the disease process (Cedernaes et al., 2014) .
The Complexities of First-in-Class Therapies The FDA defines drugs as ''addition to class'' (an addition of an alternative therapy to already existing therapies using a known mechanism), ''advance in class'' (clearly better therapies using an existing mechanism), and ''first in class'' (therapies that are first of their kind, including novel mechanisms, for treating a medical condition; Lanthier et al., 2013) . Breakthrough therapies are often first in class. There is a substantial increase in difficulty of translating a therapy to the clinic when the proposed new therapy will represent a first-in-class intervention. In fact, from 1987 to 2011, only 11 such approvals were achieved for all neurodegenerative disorders combined (Lanthier et al., 2013) . Translation is even more difficult when no previous therapy or intervention exists that has the same FDA indication. Therapies that seek an indication that is already in existence can count on a trial design that has lead to drug approval in the past. Methods to identify subjects have been worked out, and in many cases, the next drug seeking the same indication, even using a novel mechanism, needs only to ''round up the usual suspects.'' If, in contrast, no previous FDA indication exists, there will be many issues to address that extend beyond the success of the underlying scientific concept. One would need to understand the potential regulatory pathway to get such a therapy approved, consider the target population, and think through some basic aspects of how an appropriately designed clinical trial would look. As aptly stated, ''not everything that counts can be counted'' (Cameron, 1963) . In these cases, a different type of translation comes into play, namely the translation of a potential drug effect into a study design that leads to an FDA indication.
It is fundamentally important to recognize that aspects of the clinical trial leading to an FDA indication will need to be considered even as the translational science is undertaken. If there is no way to translate the benefit of the drug to the clinic through a successful trial, the therapy will likely end up lost in translation, with the science community wondering why the funding for moving the therapy forward is not forthcoming. Some issues that will be critical to consider when planning preclinical strategies are discussed below. Indication Even as the preclinical science is completed, it is important to think about how the FDA indication will be worded. The wording of the indication will directly impact the conduct of any study. For reference, the reader is referred to an online resource on FDA guidance for the approval of drugs (http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/default.htm). Why is this important to the preclinical scientist? A therapy may be modeled in animals to have an effect that cannot be proven in humans and therefore would not lead to an indication the FDA will accept. For example, the FDA has commented that they would have difficulty labeling a therapy as preventative in some cases, unless the timing of disease onset is clearly understood. If not, the intervention may only delay, and not prevent, onset. In another example, a therapy is not intended to impact the clinical manifestations of disease, but only a surrogate that is known to be associated with disease progression (for example amyloid accumulation in Alzheimer's disease). The surrogate approach must be discussed in advance with the FDA, as it might not be accepted for any indication unless a clinical change can be demonstrated within the study (Katz, 2004) . Timing What is the timing and duration of the intervention? What is a feasible timing for therapy administration in the patient population (e.g., before an insult, within minutes, hours, days)? What is the timing of the expected effect? Why is this important to the preclinical scientist? To translate any benefit of the intervention from animal models to human, the timing of intervention must match. For example, many interventions for acute stroke appeared to work in animal models but failed in humans, presumably because there was no way to intervene in humans in the same time frame as the animal (Fisher et al., 2009 ). Scientists should be wary of designing a chronic therapy for disease prevention. Patients who do not yet have a disease will be less likely to be compliant if an intervention needs to be taken chronically for a long duration. Notably, compliance may improve if there is an apparent biomarker to monitor (for example, maintaining a low cholesterol number encourages patients to take statins). The preclinical science should inform on expected duration of therapy to see an effect. If the intention is to prevent decline in conditions such as ALS, the slope of decline should be understood so that the trial duration needed to see a useful effect can be determined and deemed feasible. FDA studies need to have control groups, often consisting of placebo. In some diseases, such as epilepsy and multiple sclerosis, it may be difficult, and even possibly unethical, to maintain patients in placebo controlled trials long term, with no change in underlying therapy, so the duration of treatment needed for the treatment to be effective must be short enough to be feasible in a trial. This will vary by disease state. Population Who will be the intended target of therapy? Will they be recruitable? Where will they be found? It is much easier to recruit a population that has a chronic disease, and in whom treatment can begin at any point after the disease appears (for example epilepsy, multiple sclerosis), than it is to recruit a population at a specific point in their illness (for example, at the time of diagnosis). Furthermore, geographic limitations to neurological care may even introduce variability in the diagnosis among patients with the same disease (i.e., patients in a rural setting may receive differences in care and clinician accessibility compared to patients in New York City). Will there be a good enough rationale (high enough chance of benefit, low enough chance of harm) for them to reasonably consider enrolling in a trial? Will there be a biomarker to increase the chances that the correct population has been chosen? If so, how difficult is it to detect the presence of the biomarker? Why is this important to the preclinical scientist? If it is difficult to identify and recruit appropriate subjects into a trial, there is little likelihood that a company will provide funding to move a therapy into the clinic. The preclinical scientist can provide proof of concept for the validity and utility of a potential biomarker using etiologically relevant animal models. Further discussion of this issue can be found below. Intervention The intervention cannot be too extreme for the population that will be recruited. For example, gene therapy will have a hard time gaining favor as a preventative therapy if not all targeted patients will eventually get the disease, but it could be considered an optimal therapy to prevent decline in the same disease. Why is this important to the preclinical scientist? As above, a mismatch here will impact on likelihood of external funding for clinical development; however, there is plenty of preclinical data emerging from rigorously conducted preclinical studies in support of intervention trials.
Proof of Concept
The likelihood that a drug will gain success in the clinic will be directly related to the ability to perform a proof-of-concept study. Proof-of-concept studies provide some early indication that an intervention has an impact on the disease of interest. They are designed to be much shorter than the trial that will eventually lead to an FDA indication and to involve fewer people. The ability to design such a study is essential because it often provides the early evidence that attracts enough funding for a larger study and may also provide early evidence that a dose or duration of treatment is sufficient or insufficient. Why is this important to the preclinical scientist? As preclinical studies evolve, the scientist should consider how to model a proof-of-concept study or find an intermediate signal in an animal model that can also be used in humans and suggests target validation (that is to say that the therapy has engaged the expected target of intervention). This information will make the therapy much more attractive for development.
Understanding the Targeted Human Disease
As noted above, an important consideration in translating therapy in neurologic disorders from animal models to clinical trials in humans is a thorough understanding of the burden of the disease as well as the burden of therapy in the target population. This is particularly true for therapies for disease prevention and disease modification applied to an at-risk population where only a proportion of patients develop the disorder of interest. Examples of such applications include preventing epilepsy following a neurologic insult (Schmidt et al., 2014) , reducing the risk of Alzheimer's disease in a population with minimal cognitive impairment (Mattson, 2004) , or preventing multiple sclerosis following an isolated episode of optic neuritis (Berger et al., 2003) . In these clinical trials, many individuals would be given the experimental therapy to prevent a disease outcome that they would have possibly never gone on to develop. In this situation, patients must be willing to accept the risks of therapy. An estimate of the number needed to treat (NNT), the number of at-risk patients that need to be exposed to treatment to prevent one patient from developing the disorder (Cook and Sackett, 1995) , can be helpful to determine if future clinical trials would be feasible and ethically acceptable. As a corollary to the number needed to treat, the number needed to harm represents the number of patients that would suffer an adverse outcome related to the therapy (McAlister et al., 2000) ; this should be understood early in the translational process. Therefore, prior to beginning a translational endeavor, one must have a complete understanding of the rates and time course of the outcome that is targeted for prevention or modification in the clinical population. One must also understand the severity of the disorder that is to be prevented and what the rate of effectiveness of existing symptomatic treatments is. For instance, following moderate to severe traumatic brain injury (moderate-severe TBI), 11% of patients will develop epilepsy over the next 3-5 years (Annegers et al., 1998) (Figure 2) . A proposed treatment that reduces the risk of epilepsy by 30%, a degree of risk reduction that is commonly seen in disease-modifying treatments in clinical medicine such as statin therapy to prevent myocardial infarct and stroke (Baigent et al., 2005) , would need to be given to 30 patients with moderate-severe TBI to prevent one case of epilepsy. If the same hypothetical treatment is associated with a 1:500 risk of serious hepatic injury, there will be one case of significant harm for $17 cases of epilepsy that are prevented, most likely in an individual that would have been unlikely to develop epilepsy anyway. Assuming that for about $60% of patients who develop epilepsy following moderate-severe TBI, seizures can be fully controlled with available safe and effective antiseizure drugs, one individual will suffer harm for every seven cases of treatment-resistant epilepsy prevented. Is this an ethically acceptable ratio? To answer this in the context of developing a novel clinical therapy, one must consider the burden to society for life-long treatment and care of those seven individuals versus the single patient who may suffer irreversible medical harm from that investigational agent. In addition to potential side effects of medications, one must also consider the potential burden of therapy when determining whether a novel therapy would be feasible and acceptable. The burden of therapy may include route of therapy (oral treatment versus intravenous or intrathecal treatments), duration of treatment (a single dose of an intravenous (i.v.) medication may be less burdensome than daily long-term treatment with an oral agent), and cost of therapy. While all of these factors can be improved through technical advances in the clinical drug development process, the initial burden of therapy of a novel treatment may impact the feasibility of pivotal clinical trials; if the treatment appears more burdensome than the outcome, such trials will be costly and suffer recruitment challenges. Such challenges may make the translation of a potentially impactful therapy less than appealing.
Improving Clinical Trial Feasibility and Reducing NNT through Biomarkers
One potential method to reduce the size of disease modification trials, limit the NNT, and enhance feasibility is to identify subpopulations that are at higher risk for developing the target disorder. For epilepsy that occurs following an acute neurological insult, epidemiological studies have identified clinical features of such high-risk populations, which may be useful in identifying patients for a potential clinical trial. For instance, about 3.8% of patients develop epilepsy within 3 to 5 years of an ischemic stroke (Kwan, 2010 ). An intervention that reduces the risk of poststroke epilepsy by 50% yields a NNT of 53. However, patients who present with acute seizures at stroke onset are at greater risk of developing poststroke epilepsy, i.e., about 10% at 3-5 years, and the same intervention would require a NNT of 20. While this reduction in NNT based on clinically defined subpopulations is a significant improvement, it may remain unacceptably high for treatments that are risky or burdensome. Biological markers have the potential to further select those at highest risk for developing the disorder and exclude those at low risk for clinical trials of disease-modifying agents. In antiepileptogenesis research, gene polymorphism, soluble proteins in the serum or cerebrospinal fluid (CSF), neuroimaging characteristics, or electrophysiological markers have been proposed to identify patients most likely to develop epilepsy after neurologic insult (Engel, 2011) . Identifying reliable biomarkers should be an integral part of the development of novel therapies targeting disease prevention or modification. However, one must also be aware of the feasibility of employing a promising biomarker in both clinical trials and On the left, the circle represents a population who suffers an incident of moderate-severe TBI and is treated with an investigational antiepileptogenic agent. Only a small proportion ($10%) would have developed epilepsy over time (blue shading), leading to large sample sizes required to demonstrate an effect and, if effective in reducing the incidence of posttraumatic epilepsy by 30%, a large number needed to treat. A theoretical biomarker of epilepsy risk following TBI (green shading, 40%) may increase the proportion of the treated subjects who would have developed epilepsy, reducing sample size and NNT. However, the biomarker may not identify all individuals who will develop posttraumatic epilepsy, and the effect of treatment on the group without the biomarker would be unknown. In addition, posttraumatic epilepsy represents a small proportion of all new acquired epilepsies (purple shading) and an even smaller proportion of all incident epilepsy (right circle), suggesting that interventions that are specific to preventing epilepsy following TBI and not other causes of postinjury epilepsy may have little impact on the overall burden of epilepsy.
clinical practice. MRI-based biomarkers to predict risk for developing epilepsy are currently the subject of active clinical and preclinical investigation (Gomes and Shinnar, 2011) . Febrile status epilepticus (FSE) in infants and young children is associated with an estimated 7%-9% cumulative incidence of late temporal lobe epilepsy (Annegers et al., 1987; Verity and Golding, 1991) and has been particularly linked with hippocampal sclerosis in retrospective studies of individuals with treatment-resistant epilepsy (Koepp, 2000; Shinnar, 2003) . The ongoing NINDS-sponsored FEBSTAT study aims to prospectively study the risk of developing temporal lobe epilepsy after FSE and identify potential MRI, serological, clinical, genetic, and EEG features that may predict risk . Of the 226 children enrolled in this multicenter study, 9.7% had evidence of acute hippocampal injury (increased T2 signal intensity) immediately after their FSE episode (Lewis et al., 2014; Shinnar et al., 2012) . Repeat imaging in the subset of these patients that followed up with repeat imaging at 1 year demonstrated persistent hippocampal abnormalities, including hippocampal sclerosis and volume loss, features associated with mesial temporal lobe epilepsy. While MRI evidence of acute hippocampal injury may ultimately be a useful biomarker to predict which patients with FSE will go on to develop temporal lobe epilepsy, the utility of this biomarker for selecting high-risk populations for antiepileptogenic treatment trials may be limited. Even assuming that acute MRI changes were 90% predictive of developing epilepsy, an adequately powered (1 À b = 0.9, a = 0.05) randomized clinical trial of a treatment that reduced the risk of subsequent epilepsy by 30% would require 92 children with FSE and acute MRI changes. However, in order to identify these subjects, 900 or more children with FSE would need to undergo MRI imaging of the brain, typically under sedation, with the associated costs and risks. In this case, serological biomarkers, also under investigation in the FEBSTAT trial, may be more practical and feasible for identifying populations at high risk for epilepsy to target interventions.
The Impact of Target Expression on Successful
Translation from the Lab to the Clinic As stated above, an understanding of the basic mechanisms underlying disease initiation and progression is critical to the translational scientist in his/her pursuit of more effective therapies for the treatment, prevention, and cure of the intended disease state. Unfortunately, full knowledge of the pathophysiological processes that lead to most neurological diseases has yet to be fully elucidated. A complicating factor is whether an observed change in the neurobiological substrate is causative or secondary to the onset and progression of the disease state. In the absence of this critical information, therapy development will likely continue to be incremental rather than transformative. Incremental changes have, over a slower time span, certainly lead to improvements in therapies for many of the neurological disorders, particularly when it comes to symptomatic treatments. This certainly doesn't imply that the community should abandon attempts to translate knowledge, no matter how complete, to improve therapy. Each attempt to utilize current understanding for therapeutic intervention provides important information concerning the validity of a given target.
Timing of Intervention
For the most part, many of the neurological disease states are associated with some insult to the brain that might include gene mutation or genetic susceptibility, direct injury, or exposure to some environmental toxin that by themselves or in combination with each other lead, over some period of time, to the development of the disease state (Figure 1) . The time period from the initial trigger to the onset of disease symptoms can vary and can be influenced by many other causes that might include, among other factors, age and genetic background. Regardless of the disease state, knowledge of these disease-producing factors during the period of disease genesis provides the translational scientist with one or more therapeutic targets and, importantly, a window of opportunity for evaluating therapy intervention.
Intervention early in the disease process has the potential of preventing disease onset. Alternatively, early intervention may modify the expression of disease symptoms, e.g., decreased seizure susceptibility and severity in the case of epilepsy (White and Lö scher, 2014) , reduced cognitive decline in Alzheimer's disease (Cedernaes et al., 2014; Doody et al., 2014) , or delayed neurological dysfunction, including muscle weakness, in multiple sclerosis (Vosoughi and Freedman, 2010) . Intervention when applied after disease expression would hopefully lead to improved symptomatic control of disease symptoms or, ideally, a cure. In the case of those disease states that are progressive in nature, it is hypothetically possible that intervention, even after symptoms appear, will halt disease progression. Clearly, timing of treatment intervention can result in a myriad of different outcomes.
To make the most out of a given treatment intervention, it reasons that the treatment would necessarily target one or more of the processes/targets thought to contribute to disease onset, progression, or maintenance. Furthermore, knowledge of the various targets that might be expressed early in disease onset and prior to overt expression of disease symptoms can provide an opportunity for the development of clinically relevant biomarkers that, depending on whether they are invasive or noninvasive, could provide the practicing clinician with an important means to follow disease onset and progression. For example, clinical evidence would suggest the presence of Lewy pathology within the GI tract (Lebouvier et al., 2010) , as well as olfactory dysfunction (Driver-Dunckley et al., 2014) , years prior to onset of motor symptoms of Parkinson's disease (PD), offering potentially minimally invasive biomarkers to signal intervention in the prodromal period of PD. Basic scientists have since determined that certain animal models of Parkinson's disease replicate this clinical phenomenon of Lewy pathology in the GI tract (Sharrad et al., 2013) , highlighting the utility of cross-communication of clinical observations between clinician and basic researcher to define the most etiologically relevant preclinical animal models of a particular neurological disease. Importantly, the better any given biomarker predicts disease onset and tracks with disease progression, the more useful it will ultimately be for assessing the impact of a specific therapy intervention.
As illustrated in Figure 1 , the targets that manifest early in the disease process prior to symptom onset are not necessarily identical to those that might emerge with disease progression, hence the importance of understanding the timeline and pathophysiology of disease progression. For most neurological disease states, it is not known whether the expression of a particular molecular or genetic target is an epiphenomenon of the disease process or contributes to the maintenance and progression of the disease. Further, many of the targets that develop secondary to disease onset might reflect compensatory attempts of the brain to correct the basic defect(s) that led to disease onset. Obviously, the greater the understanding of the relevance and timing of target expression to disease onset and progression is, the more impactful the consequences of developing and implementing target-specific therapies are. In this regard, the development of target-specific biomarkers can play an important role in understanding the contribution of each target to the disease process and the impact of treatment on disease onset and progression. In the absence of a clear understanding of the role of a particular target in the disease process, treatment with the wrong therapy could actually lead to a worsening of outcome. One such unfortunate example is that from preclinical and subsequent clinical studies with minocycline for the potential treatment of ALS. In the preclinical mouse models evaluated (Zhu et al., 2002) , minocycline showed strong promise of potential efficacy, whereas clinical trials with minocycline actually exacerbated disease progression (Gordon et al., 2007 . Thus, the understanding of the pathophysiology or associated targets can make all the difference in the clinical disease outcome.
When it comes to symptom control, the chronic nature of most neurological disorders often necessitates chronic treatment in order to offer the patient the best possible outcome. However, the nature of the treatment approach likely changes as the disease progresses and symptoms change in severity or phenotype. Ideally, basic science will someday provide the clinician with a greater ability to select the best therapy on the basis of measurable changes in the disease state. For example, the ability to predict which patient will undergo a remission in their disease, and when that remission will occur, using disease-specific biomarkers would represent a significant advance to the care of a patient with a chronic neurological disease.
Unfortunately, translating knowledge about disease cause, onset, and progression is difficult at best. The clinical literature is replete with examples wherein the specific cause of a disease has been known for years, or in some cases decades, and yet no preventative or curative treatment has emerged as a result of that knowledge, i.e., familial forms of ALS, Huntington's, and environmentally induced Parkinson's disease to name a few. The hope lies in the fact that there is a growing interest in translational science at the basic and clinical level. Scientists working together in their efforts to develop more and more etiologically relevant model systems will undoubtedly provide a greater understanding of the pathology of neurological disease states. From this information will come target-specific therapies that can be tested in a systematic and hypothesis-driven manner using these new model systems, the results of which will provide further insight into the importance of a particular target to the onset of the disease and expression of disease symptoms. With this information, hopefully a translatable process will emerge that quickly and efficiently takes the most appropriate therapy to the patient population at risk.
Predicting Tolerability to Therapies through Preclinical Evaluation
In addition to efficacy, toxicity and tolerability should be important differentiation factors of preclinical testing efforts. Toxicity will be more important for acute therapies. For therapies that will be prescribed for chronic use, both potential for toxicity and chronic tolerability will be of critical importance to the success of an intervention. This is particularly important when established therapies already exist. Most preclinical adverse effects can be argued to demonstrate a certain degree of translational relevance and predictive validity. For example, preclinical screening in model organisms or systems can often rule out the potential for adverse cardiovascular and hepatic liabilities, e.g., assessing potential effects on hERG channels prior to first-in-man studies (Mö ller, 2010) . However, the heterogeneity and diversity of human patient populations makes complete translation nearly impossible with seemingly genetically indistinguishable animal models (e.g., C57BL/6 mice or SpragueDawley rats from a single breeding facility). We simply cannot anticipate the potential for every nuance of clinical treatmentemergent adverse events when evaluating the preclinical profile of an investigational agent, as the more subtle adverse events only become apparent with long-term dosing in large patient populations. Fortunately, compounds in preclinical development can undergo evaluation of essential predictive indicators of basic safety and tolerability that will be useful for future clinical applications. It is important to note that absence of toxicity in an animal model does not necessarily indicate that the drug will be well tolerated in the clinic. Industry research would suggest that rodent and nonrodent safety evaluations lasting up to 1 month can effectively predict over 70% of the organ toxicities observed in man (Olson et al., 2000) . Chronic safety studies and the determination of maximal tolerated doses in rodents give some essential safety pharmacology insight required for FDA applications (Redfern et al., 2013 ).
Yet, these safety pharmacology assessments do not necessarily predict the tolerability of a promising investigational agent in patients. For this reason, a very useful measure for assessment and differentiation of preclinical candidate compounds is the protective index (PI). PI is obtained by measuring the dose required to produce a desired biological response endpoint in 50% of individuals (ED 50 ) and the dose that produces an adverse behavioral endpoint in 50% of individuals (TD 50 ), with PI being TD 50 /ED 50 . PI thus offers an indication of the margin of safety that defines an investigational agent. PI is useful to estimate the potential for tolerability in a clinical setting because it can allow for the estimation of some potential adverse effects at physiologically relevant doses, as well as in the context of overdose or patient nonadherence (Samsonsen et al., 2014) . PI provides some, albeit incomplete, insight into the margin of safety at which a drug can be used in the absence of adverse motor, behavioral, or cognitive effects. For this reason, PI is somewhat useful to anticipate how well tolerated an agent may be in a clinical setting. Notably, some important adverse events in the clinic may not be discovered in preclinical animal models. Additionally, it is essential to consider that potency alone is not predictive of clinical efficacy. A compound may elicit a desired biological response in the nanomolar range, but does it also carry the potential to induce adverse effects, including sedation, motor impairments, or worse, cognitive deficits, when the dose is as little as doubled? Potency essentially becomes meaningless if the protective index is narrow. Conversely, an agent that is both potent and demonstrates a wide PI, i.e., the dose required to elicit an adverse effect is several orders of magnitude greater than the effective dose, would become a more favorable clinical candidate due to the greater likelihood for tolerability by a diverse patient population. This represents an often underconsidered, but essential, piece of preclinical data that is essential for differentiating investigational agents. When a compound has a narrow PI, it can be anticipated that the risk for adverse events is significantly more probable than that which is present in a compound with a wide PI. For example, if a patient misses a dose, only to ''double up'' upon realizing this occurrence, will he/she be at risk for significant acute adverse effects as a result? Thus, using protective index in addition to safety pharmacology measures may provide greater insight into the potential clinical tolerability of a promising novel treatment.
One example of a compound that demonstrates robust preclinical potency is Huperzine A. Huperzine A is an isolated natural product derived from Chinese club moss (Huperzia serrata) that has been used for centuries as a homeopathic treatment for swelling, fever, inflammation, and schizophrenia (Zangara, 2003) . More recently, Huperzine A has demonstrated evidence for preclinical efficacy in animal models of seizure and epilepsy (Bialer et al., 2009; Coleman et al., 2008; Schneider et al., 2009; Tonduli et al., 2001) . With approximately 30% of patients with epilepsy resistant to currently available treatments (Brodie and Kwan, 2002) , identifying treatments that may be effective for patients with pharmacoresistant epilepsy is heavily demanded by the epilepsy research community (Kelley et al., 2009; Lowenstein, 2011) . One mouse model that has demonstrated promise in the early differentiation of drugs that may be effective against pharmacoresistant epilepsy is the 6 Hz model of partial seizures (Barton et al., 2001) . Thus, compounds that demonstrate efficacy in this assay may ultimately provide clinical utility to the patient with pharmacoresistant epilepsy. Huperzine A demonstrates robust potency in this particular in vivo model of pharmacoresistant partial seizures, suggesting that it could be very effective for the patient with pharmacoresistant epilepsy. The high potency of Huperzine A in this particular assay at the 32 mA stimulation intensity is striking compared to other antiseizure drugs (ASDs). Specifically, the intraperitoneal (i.p.) ED 50 of Huperzine A is 0.34 mg/kg, whereas other ASDs are substantially less potent in this assay, demonstrating ED 50 s at least 40-fold greater (as an example, phenobarbital: 14.8 mg/kg; Barton et al., 2001 ). However, this compound is a useful example of the importance of a wide therapeutic index to more clearly predict in vivo tolerability in the clinic. The ED 50 of Huperzine A at the 44 mA stimulation intensity is 0.78 mg/kg, which is very near to the TD 50 of 0.83 mg/kg (i.p.) such that the PI is 1.06 in this assay. As was discussed above, should a patient need to escalate doses or inadvertently increase the daily dose of a highly potent compound, would a compound with a narrow PI in a model of pharmacoresistant seizures confer an increased risk for treatment-emergent adverse events or even failure to comply because of cognitive/motor impairments? This hypothetical example aside, the real tolerability and safety of any new therapy has to depend on the conduct of appropriate clinical evaluation and long-term postmarketing surveillance. Nonetheless, these considerations are important to make when considering advancing a candidate compound to the clinic. In the case of Huperzine A, there is no evidence to date that it possesses a narrow therapeutic index in humans. In fact, this compound is currently available in vitamin and supplement stores without prescription and has been used for centuries as a homeopathic remedy for numerous ailments.
Furthermore, it is essential to consider whether a highly potent compound is something that can be reasonably administered to a heterogenous patient population. Pharmacogenetic variability in patient populations should inevitably compel a preclinical and clinical investigator to carefully evaluate the use of highly potent or narrow PI compounds in a clinical setting. The potential for individual genetic variability may also compel clinical and basic scientists to collaborate to develop better-tolerated therapies through a more comprehensive understanding of the factors associated with poor tolerability. For example, carbamazepine and oxcarbazepine use by patients with the specific HLA genotype, HLA-B*15:02, carries a significantly elevated risk for developing life-threatening cutaneous adverse drug reactions (cADRs), including Stevens-Johnson syndrome (Kaniwa and Saito, 2013) . Because of this increased risk for cADRs in patient populations carrying this genetic polymorphism, some countries have even begun to prescreen patients for this polymorphism as a biomarker to avoid such life-threatening events. While carbamazepine is considered to have a wide safety margin in models of generalized tonic-extension seizure (MES ED 50 of 7.8 mg/kg versus a TD 50 of 45.4 mg/kg in mice; Barton et al., 2001) , the risk for adverse events in special patient populations will significantly and understandably affect tolerability. Genetic polymorphisms thus introduce added complexity to the issue of tolerability in the clinical space. While a compound may demonstrate robust preclinical efficacy in homogenous populations of rodent and nonrodent models, the ability to anticipate pharmacogenetically derived adverse events is less realistic to model in the preclinical space. For this reason, the use of a highly potent compound with a narrow preclinical PI in the clinical setting should be conducted with caution and rigorous observation due to the risk for treatment-emergent adverse events in large patient populations. Thus, while a highly potent compound may, in theory, hold great promise for clinical impact, the more likely scenario is that a compound may be too potent for clinical efficacy studies without careful monitoring of patient outcomes.
To better predict the tolerability issues that may arise in a clinical setting, it is essential to understand the main tolerability issues that present in the specific patient population and to try to devise ways to screen for these in animal models. For example, one major issue that routinely causes tolerability issues in the patient with epilepsy is cognitive adverse effects associated with ASD use (Eddy et al., 2011; Hermann et al., 2010; Ijff and Aldenkamp, 2013) . As epilepsy itself is already associated with significant impact on learning and memory (Brooks-Kayal et al., 2013; Murphy, 2013) , compounding such effects with agents known to induce cognitive impairments only worsens the likelihood for poor tolerability (Eddy et al., 2011) . While newer ASDs are often more well tolerated because of the reduced prevalence of toxic side effects, including effects on cognition, the cost-savings, experience with, and wide availability of older ASDs causes them to still be prescribed on a routine basis. Thus, tolerability issues and nonadherence remain clinically pervasive. For these reasons, the NINDS Epilepsy Benchmarks now includes the demand for increased effort to identify the potential for adverse cognitive comorbidities early in the drug discovery and development process (Kelley et al., 2009 ). Animal models of learning and memory have long been used to understand the cognitive liability of various pharmacological manipulations, with some models demonstrating greater translational relevance than others. The Morris water maze (MWM; Morris, 1984 ) is one such well-validated rodent model of learning (Wenk, 2004) that is highly translatable to the clinical setting because patients with hippocampal lesions also demonstrate deficits in cognitive performance in tasks similar to the rodent MWM (Bohbot et al., 1998) . The assessment of cognitive performance in the MWM in the preclinical arena can follow a neurological insult, i.e., post pilocarpine-induced SE (Cunha et al., 2009; White et al., 2012) , post-TBI (Dash et al., 2010) , or simply the effect of an investigational agent on naive or chronically diseased animals (Detrait et al., 2010) .
As third and fourth generation ASDs are beginning to progress to the clinic (Krauss et al., 2014; Steinhoff et al., 2014) , it is presently difficult to predict whether efforts to evaluate cognitive liability of novel investigational agents in animal models of cognitive function, which may be predictive of clinical tolerability, will ultimately result in greater tolerance of these novel agents by patients with epilepsy. As mentioned above, most preclinical studies are performed with acute dosing in naive animal models, whereas clinical experience and evidence would suggest that adverse effects are often more likely to emerge after chronic dosing in a patient population. Thus, whether acute preclinical studies will accurately predict or model adverse events in patients with chronic disease is still under debate and investigation. However, ample clinical evidence of cognitive impairment with various older ASDs (Eddy et al., 2011) suggests that identifying similar behavioral deficits, or biomarkers thereof, in animal models of learning and memory could provide a valid preclinical screening approach for promising investigational agents. Only then will the ideal preclinical platform to predict clinical tolerability for this important clinical endpoint become available to develop promising and better-tolerated drugs.
How Do We Translate Windows of Treatment
Opportunity from Models to Humans An important aspect of translational research is to understand how to map windows of treatment opportunity from model systems to human disease. For example, in most mouse models of Alzheimer's disease, behavioral changes occur between 3 and 18 months of life (Kobayashi and Chen, 2005) , whereas most human disease becomes apparent in the seventh and eighth decades of life. How do we identify comparable time points between the model and the human disease process for intervention? For symptomatic therapies aimed at reducing memory problems in affected individuals, the window of treatment opportunity may be broad and readily apparent. However, for treatments designed to arrest or slow the disease process in presymptomatic individuals, one must also develop tools to define the optimal window for intervention as part of the preclinical process. If a disease involves a cascading sequence of processes as shown in Figure 1 , each with transient expression of a target, one needs to understand when that target is expressed in human disease in order to define the appropriate clinical population for treatment. Identifying biomarkers of target expression that can be readily assessed in humans is an integral part of the preclinical process. Furthermore, if the disorder is an infrequent outcome in an at-risk population, such as seizures following TBI, serum markers or other minimally invasive and scalable tests are needed to ensure that a clinical study is feasible.
Conclusion
Increasingly, basic and clinical researchers need to collaborate in their research endeavors to improve the likelihood that translational research will be successful in treating the affected patient. In the absence of such collaboration, novel treatments identified by the basic researcher may continue to fail in clinical studies. Such collaborations are popping up in several neurologic disease areas, as exemplified by the STAIR (Stroke Therapy Academic Industry Round Table) initiative in stroke (Fisher et al., 2009 ) and the collaboration between translational and clinical scientists in epilepsy sponsored by the International League Against Epilepsy and the American Epilepsy Society . These initiatives are both ongoing efforts to bring clinicians and basic researchers to the same table, and both are ongoing. In this Perspective, we have reviewed a number of strategies related to translational drug development that may improve the chances for success, including a greater understanding of the patient populations that will be treated, issues of dose selection, timing of intervention, duration of intervention, availability of biomarkers, and likelihood that a proof-ofconcept trial can be performed. While relevant animal models exist that can be exploited by the basic researcher, additional close collaboration efforts are needed with the clinician scientist to further characterize and optimize these models for translational discovery. Through a greater understanding of the clinical pathophysiology and subsequent backtranslation to the basic researcher, it is anticipated that more relevant and impactful therapies will begin to emerge for the myriad neurological disease states that await curative, rather than symptomatic, treatment options.
